Biomarin Pharmaceutical Stock Today
| BMRN Stock | USD 84.78 0.07 0.08% |
Performance1 of 100
| Odds Of DistressLess than 3
|
Biomarin Pharmaceutical is selling at 84.78 as of the 11th of September 2024; that is 0.08 percent decrease since the beginning of the trading day. The stock's open price was 84.85. Biomarin Pharmaceutical has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Biomarin Pharmaceutical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of August 2024 and ending today, the 11th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of July 1999 | Category Healthcare | Classification Health Care |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 190.38 M outstanding shares of which 6.65 M shares are currently shorted by private and institutional investors with about 4.7 trading days to cover. More on Biomarin Pharmaceutical
Moving together with Biomarin Stock
| 0.72 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
Moving against Biomarin Stock
Biomarin Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Alexander Hardy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiomarin Pharmaceutical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biomarin Pharmaceutical's financial leverage. It provides some insight into what part of Biomarin Pharmaceutical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biomarin Pharmaceutical (BMRN) is traded on NASDAQ Exchange in USA. It is located in 770 Lindaro Street, San Rafael, CA, United States, 94901 and employs 3,401 people. Biomarin Pharmaceutical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 16.05 B. Biomarin Pharmaceutical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 190.38 M outstanding shares of which 6.65 M shares are currently shorted by private and institutional investors with about 4.7 trading days to cover.
Biomarin Pharmaceutical currently holds about 1.27 B in cash with 159.26 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.85.
Check Biomarin Pharmaceutical Probability Of Bankruptcy
Ownership AllocationBiomarin Pharmaceutical holds a total of 190.38 Million outstanding shares. The majority of Biomarin Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biomarin Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biomarin Pharmaceutical. Please pay attention to any change in the institutional holdings of Biomarin Pharmaceutical as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million two hundred ninety-four thousand six hundred four invesors are currently shorting Biomarin Pharmaceutical expressing very little confidence in its future performance.
Check Biomarin Ownership Details
Biomarin Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Norges Bank | 2024-06-30 | 3.6 M | |
| Elliott Investment Management L.p. | 2024-06-30 | 3.5 M | |
| Geode Capital Management, Llc | 2024-06-30 | 3.2 M | |
| Jpmorgan Chase & Co | 2024-03-31 | 2.4 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 2.3 M | |
| Deutsche Bank Ag | 2024-06-30 | 1.8 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.7 M | |
| Northern Trust Corp | 2024-06-30 | 1.6 M | |
| Legal & General Group Plc | 2024-06-30 | 1.5 M | |
| Blackrock Inc | 2024-06-30 | 22.7 M | |
| Vanguard Group Inc | 2024-06-30 | 19 M |
Biomarin Pharmaceutical Historical Income Statement
Biomarin Stock Against Markets
Biomarin Pharmaceutical Corporate Management
| George Davis | Chief VP | Profile | |
| Brian Mueller | Chief Accounting Officer, Group VP and Controller | Profile | |
| Traci McCarty | Group Relations | Profile | |
| Jonathan Day | Executive Science | Profile | |
| Marni Kottle | Executive Officer | Profile | |
| Humaira Serajuddin | Senior Officer | Profile | |
| Philip Scalzo | VP Officer | Profile |
Additional Information and Resources on Investing in Biomarin Stock
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.877 | Earnings Share 1.32 | Revenue Per Share 13.701 | Quarterly Revenue Growth 0.196 | Return On Assets 0.0223 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.